Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
PRQR
Valuation N/A
ProQR Therapeutics N.V.
Price$1.57
Model IV—
P/IV—
Limited data — see page
PRTA
Valuation N/A
PROTHENA CORP PUBLIC LTD CO
Price$8.61
Model IV—
P/IV—
Market implies +72.2%/yr
vs model +2.0% · above model
PTCT
Deeply undervalued
PTC THERAPEUTICS, INC.
Price$62.56
Model IV$345.26
P/IV0.21
Discount 82%
Return to IV: +451.9%
Market implies -5.1%/yr
vs model +25.0% · below model
PTGX
Valuation N/A
Protagonist Therapeutics, Inc
Price$139.91
Model IV—
P/IV—
Market implies +34.9%/yr
vs model +13.9% · above model
PTN
Valuation N/A
PALATIN TECHNOLOGIES INC
Price$9.01
Model IV—
P/IV—
Market implies -8.8%/yr
vs model +15.0% · below model
PULM
Valuation N/A
Pulmatrix, Inc.
Price$1.53
Model IV—
P/IV—
Market implies -10.4%/yr
vs model +15.0% · below model
PVLA
Valuation N/A
PALVELLA THERAPEUTICS, INC.
Price$131.34
Model IV—
P/IV—
Market implies +51.4%/yr
vs model +15.0% · above model
PYXS
Valuation N/A
Pyxis Oncology, Inc.
Price$1.99
Model IV—
P/IV—
Market implies +20.5%/yr
QCLS
Valuation N/A
Q/C TECHNOLOGIES, INC.
Price$0.64
Model IV—
P/IV—
Limited data — see page
QDEL
Deeply undervalued
QuidelOrtho Corp
Price$12.41
Model IV$44.79
P/IV0.23
Discount 72%
Return to IV: +260.9%
Market implies -19.3%/yr
vs model +17.1% · below model
QNRX
Valuation N/A
Quoin Pharmaceuticals, Ltd.
Price$4.55
Model IV—
P/IV—
Limited data — see page
QNTM
Valuation N/A
Quantum Biopharma Ltd.
Price$3.11
Model IV—
P/IV—
Limited data — see page
QTTB
Fairly valued
Q32 Bio Inc.
Price$8.09
Model IV$9.47
P/IV1.17
Discount 15%
Return to IV: +17.0%
Market implies -10.5%/yr
vs model +12.2% · below model
QUCY
Valuation N/A
Quantum Cyber N.V.
Price$1.39
Model IV—
P/IV—
Market implies +71.5%/yr
QURE
Valuation N/A
uniQure N.V.
Price$22.54
Model IV—
P/IV—
Market implies +62.7%/yr
RACC
Valuation N/A
Research Alliance Corp III
Price$10.30
Model IV—
P/IV—
Limited data — see page
RADX
Valuation N/A
Radiopharm Theranostics Ltd
Price$1.11
Model IV—
P/IV—
Limited data — see page
RANI
Valuation N/A
Rani Therapeutics Holdings, Inc.
Price$0.79
Model IV—
P/IV—
Limited data — see page
RAPP
Valuation N/A
Rapport Therapeutics, Inc.
Price$29.85
Model IV—
P/IV—
Limited data — see page
RARE
Deeply overvalued
Ultragenyx Pharmaceutical Inc.
Price$15.29
Model IV$9.87
P/IV2.43
Premium +55%
Return to IV: -35.4%
Market implies +5.7%/yr
vs model +17.6% · below model
RCKT
Valuation N/A
ROCKET PHARMACEUTICALS, INC.
Price$2.63
Model IV—
P/IV—
Limited data — see page
RCKTW
Valuation N/A
ROCKET PHARMACEUTICALS, INC.
Price$0.00
Model IV—
P/IV—
Limited data — see page
RCUS
Valuation N/A
Arcus Biosciences, Inc.
Price$23.83
Model IV—
P/IV—
Market implies +48.4%/yr
RDHL
Valuation N/A
RedHill Biopharma Ltd.
Price$0.58
Model IV—
P/IV—
Market implies +99.4%/yr
RDY
Fairly valued
DR REDDYS LABORATORIES LTD
Price$12.20
Model IV$12.79
P/IV0.97
Discount 5%
Return to IV: +4.8%
Market implies +7.7%/yr
vs model +10.0% · in line
REGN
Overvalued
REGENERON PHARMACEUTICALS, INC.
Price$739.57
Model IV$574.53
P/IV1.40
Premium +29%
Return to IV: -22.3%
Market implies +8.4%/yr
vs model +6.2% · in line
REVB
Valuation N/A
REVELATION BIOSCIENCES, INC.
Price$0.77
Model IV—
P/IV—
Limited data — see page
REVBW
Valuation N/A
REVELATION BIOSCIENCES, INC.
Price$0.01
Model IV—
P/IV—
Limited data — see page
RFL
Valuation N/A
Rafael Holdings, Inc.
Price$1.48
Model IV—
P/IV—
Market implies +108.9%/yr
vs model +2.0% · above model
RGC
Valuation N/A
Regencell Bioscience Holdings Ltd
Price$7.63
Model IV—
P/IV—
Limited data — see page
RIGL
Deeply undervalued
RIGEL PHARMACEUTICALS INC
Price$48.72
Model IV$117.12
P/IV0.26
Discount 58%
Return to IV: +140.4%
Market implies +2.5%/yr
vs model +20.0% · below model
RLMD
Valuation N/A
RELMADA THERAPEUTICS, INC.
Price$3.17
Model IV—
P/IV—
Limited data — see page
RLYB
Valuation N/A
Rallybio Corp
Price$16.99
Model IV—
P/IV—
Market implies +54.7%/yr
RMTI
Deeply overvalued
ROCKWELL MEDICAL, INC.
Price$8.02
Model IV$1.97
P/IV0.38
Premium +307%
Return to IV: -75.4%
Market implies +12.9%/yr
vs model +2.8% · above model
RNA
Valuation N/A
Atrium Therapeutics, Inc.
Price$8.26
Model IV—
P/IV—
Limited data — see page
RNAC
Valuation N/A
Cartesian Therapeutics, Inc.
Price$6.82
Model IV—
P/IV—
Market implies +80.3%/yr
RNAZ
Valuation N/A
Transcode Therapeutics, Inc.
Price$1.71
Model IV—
P/IV—
Limited data — see page
RNTX
Valuation N/A
Rein Therapeutics, Inc.
Price$0.77
Model IV—
P/IV—
Limited data — see page
RNXT
Valuation N/A
RenovoRx, Inc.
Price$1.33
Model IV—
P/IV—
Market implies +43.9%/yr
vs model +15.0% · above model
ROIV
Valuation N/A
Roivant Sciences Ltd.
Price$34.21
Model IV—
P/IV—
Market implies +139.9%/yr
vs model +2.0% · above model
RPRX
Deeply undervalued
Royalty Pharma plc
Price$56.21
Model IV$108.10
P/IV0.52
Discount 48%
Return to IV: +92.3%
Market implies -4.9%/yr
vs model +3.7% · below model
RYTM
Deeply overvalued
RHYTHM PHARMACEUTICALS, INC.
Price$89.64
Model IV$24.98
P/IV3.93
Premium +259%
Return to IV: -72.1%
Market implies +15.1%/yr
vs model +50.0% · below model
RZLT
Valuation N/A
Rezolute, Inc.
Price$4.64
Model IV—
P/IV—
Limited data — see page
SBFM
Valuation N/A
Sunshine Biopharma Inc.
Price$0.43
Model IV—
P/IV—
Market implies -50.0%/yr
SBFMW
Valuation N/A
Sunshine Biopharma Inc.
Price$0.03
Model IV—
P/IV—
Market implies -50.0%/yr
SCNX
Valuation N/A
Scienture Holdings, Inc.
Price$3.86
Model IV—
P/IV—
Market implies +81.1%/yr
vs model +2.0% · above model
SCYX
Valuation N/A
SCYNEXIS INC
Price$4.22
Model IV—
P/IV—
Market implies +21.3%/yr
vs model +11.9% · above model
SDEV
Valuation N/A
Stablecoin Development Corp
Price$1.99
Model IV—
P/IV—
Market implies +7.6%/yr
vs model +15.0% · below model
SDGR
Deeply overvalued
Schrodinger, Inc.
Price$26.39
Model IV$4.40
P/IV3.46
Premium +500%
Return to IV: -83.3%
Market implies +26.4%/yr
vs model +16.7% · above model
SEPN
Fairly valued
Septerna, Inc.
Price$36.90
Model IV$41.19
P/IV0.73
Discount 10%
Return to IV: +11.6%
Market implies +5.5%/yr
vs model +10.0% · below model
SER
Valuation N/A
Serina Therapeutics, Inc.
Price$2.01
Model IV—
P/IV—
Market implies +83.1%/yr
vs model +2.0% · above model
SGMT
Valuation N/A
Sagimet Biosciences Inc.
Price$8.92
Model IV—
P/IV—
Market implies +65.6%/yr
SHPH
Valuation N/A
Shuttle Pharmaceuticals Holdings, Inc.
Price$5.55
Model IV—
P/IV—
Limited data — see page
SIGA
Deeply undervalued
SIGA TECHNOLOGIES INC
Price$3.28
Model IV$7.77
P/IV0.60
Discount 58%
Return to IV: +137.0%
Market implies -10.1%/yr
vs model +3.5% · below model
SILO
Valuation N/A
Silo Pharma, Inc.
Price$1.45
Model IV—
P/IV—
Market implies +60.4%/yr
SION
Valuation N/A
Sionna Therapeutics, Inc.
Price$4.90
Model IV—
P/IV—
Limited data — see page
SKYE
Valuation N/A
Skye Bioscience, Inc.
Price$1.68
Model IV—
P/IV—
Limited data — see page
SLGL
Valuation N/A
Sol-Gel Technologies Ltd.
Price$70.34
Model IV—
P/IV—
Market implies +32.9%/yr
vs model +2.0% · above model
SLN
Valuation N/A
Silence Therapeutics plc
Price$9.52
Model IV—
P/IV—
Market implies +108.7%/yr
SLS
Valuation N/A
SELLAS Life Sciences Group, Inc.
Price$11.26
Model IV—
P/IV—
Market implies +113.9%/yr
vs model +15.0% · above model